$MYGN
MYRIAD GENETICS INC

2014 Q3 Form 10-Q Financial Statement

#000119312514397661 Filed on November 05, 2014

View on sec.gov

Income Statement

Concept 2014 Q3 2013 Q3
Revenue $168.8M $202.5M
YoY Change -16.63% 51.73%
Cost Of Revenue $32.80M $21.44M
YoY Change 52.99% 53.88%
Gross Profit $136.0M $181.0M
YoY Change -24.87% 51.48%
Gross Profit Margin 80.57% 89.41%
Selling, General & Admin $85.40M $77.28M
YoY Change 10.51% 37.68%
% of Gross Profit 62.79% 42.69%
Research & Development $22.60M $16.80M
YoY Change 34.5% 47.39%
% of Gross Profit 16.62% 9.28%
Depreciation & Amortization $2.600M $2.400M
YoY Change 8.33% 8.55%
% of Gross Profit 1.91% 1.33%
Operating Expenses $108.0M $94.08M
YoY Change 14.79% 39.32%
Operating Profit $25.90M $82.90M
YoY Change -68.76% 70.65%
Interest Expense $100.0K $1.400M
YoY Change -92.86% 0.0%
% of Operating Profit 0.39% 1.69%
Other Income/Expense, Net -$43.00K $923.0K
YoY Change -104.66% -25.56%
Pretax Income $25.90M $83.83M
YoY Change -69.1% 68.25%
Income Tax $9.900M $28.36M
% Of Pretax Income 38.22% 33.83%
Net Earnings $16.00M $55.47M
YoY Change -71.15% 84.05%
Net Earnings / Revenue 9.48% 27.39%
Basic Earnings Per Share $0.22 $0.70
Diluted Earnings Per Share $0.21 $0.68
COMMON SHARES
Basic Shares Outstanding 72.80M shares 79.58M shares
Diluted Shares Outstanding 76.10M shares 81.80M shares

Balance Sheet

Concept 2014 Q3 2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $159.6M $357.0M
YoY Change -55.29% 2.23%
Cash & Equivalents $69.80M $84.99M
Short-Term Investments $89.80M $272.0M
Other Short-Term Assets $64.00M $13.70M
YoY Change 367.15% 25.69%
Inventory $24.78M
Prepaid Expenses $9.419M $4.857M
Receivables $75.72M $86.22M
Other Receivables $11.24M $1.800M
Total Short-Term Assets $335.4M $458.7M
YoY Change -26.88% 5.41%
LONG-TERM ASSETS
Property, Plant & Equipment $43.42M $30.68M
YoY Change 41.56% 23.9%
Goodwill $169.2M $56.85M
YoY Change 197.59% 0.0%
Intangibles $202.0M $13.09M
YoY Change 1443.34% -15.28%
Long-Term Investments $54.10M $158.6M
YoY Change -65.89% 35.44%
Other Assets $5.000M $41.50M
YoY Change -87.95% 21.7%
Total Long-Term Assets $473.6M $323.0M
YoY Change 46.65% 20.55%
TOTAL ASSETS
Total Short-Term Assets $335.4M $458.7M
Total Long-Term Assets $473.6M $323.0M
Total Assets $809.0M $781.7M
YoY Change 3.5% 11.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $25.73M $18.75M
YoY Change 37.25% 69.09%
Accrued Expenses $40.65M $59.39M
YoY Change -31.55% 38.13%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $67.73M $79.03M
YoY Change -14.3% 37.79%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $24.50M $12.40M
YoY Change 97.58% 22.77%
Total Long-Term Liabilities $24.50M $12.40M
YoY Change 97.58% 22.77%
TOTAL LIABILITIES
Total Short-Term Liabilities $67.73M $79.03M
Total Long-Term Liabilities $24.50M $12.40M
Total Liabilities $96.86M $91.39M
YoY Change 5.99% 35.4%
SHAREHOLDERS EQUITY
Retained Earnings -$17.45M $13.96M
YoY Change -225.04% -193.05%
Common Stock $729.0K $768.0K
YoY Change -5.08% -5.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $712.2M $690.3M
YoY Change
Total Liabilities & Shareholders Equity $809.0M $781.7M
YoY Change 3.5% 11.18%

Cashflow Statement

Concept 2014 Q3 2013 Q3
OPERATING ACTIVITIES
Net Income $16.00M $55.47M
YoY Change -71.15% 84.05%
Depreciation, Depletion And Amortization $2.600M $2.400M
YoY Change 8.33% 8.55%
Cash From Operating Activities $7.000M $90.48M
YoY Change -92.26% 76.19%
INVESTING ACTIVITIES
Capital Expenditures -$11.50M -$5.300M
YoY Change 116.98% 112.0%
Acquisitions
YoY Change
Other Investing Activities $39.10M -$2.800M
YoY Change -1496.43% 12.0%
Cash From Investing Activities $27.60M -$8.057M
YoY Change -442.56% 60.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $45.60M $102.3M
YoY Change -55.43% 121.47%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -28.90M -101.5M
YoY Change -71.53% 173.47%
NET CHANGE
Cash From Operating Activities 7.000M 90.48M
Cash From Investing Activities 27.60M -8.057M
Cash From Financing Activities -28.90M -101.5M
Net Change In Cash 5.700M -19.09M
YoY Change -129.86% -306.76%
FREE CASH FLOW
Cash From Operating Activities $7.000M $90.48M
Capital Expenditures -$11.50M -$5.300M
Free Cash Flow $18.50M $95.78M
YoY Change -80.69% 77.85%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
104073000
CY2014Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2014Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
73497000 shares
CY2014Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
73497000 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
CY2014Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
23.30
CY2014Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2014Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
14238603 shares
CY2014Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
65013000
CY2014Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q2 us-gaap Liabilities Current
LiabilitiesCurrent
80578000
CY2014Q2 us-gaap Common Stock Value
CommonStockValue
735000
CY2014Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1515000
CY2014Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
23078000
CY2014Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2004000
CY2014Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
56410000
CY2014Q2 us-gaap Stockholders Equity
StockholdersEquity
718998000
CY2014Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
823814000
CY2014Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
8238000
CY2014Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
717774000
CY2014Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1090000
CY2014Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
24238000
CY2014Q2 us-gaap Liabilities
Liabilities
104816000
CY2014Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
8968000
CY2014Q2 us-gaap Available For Sale Equity Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleEquitySecuritiesAccumulatedGrossUnrealizedGainBeforeTax
383000
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64821000
CY2014Q2 us-gaap Goodwill
Goodwill
169181000
CY2014Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
34594000
CY2014Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
225405000
CY2014Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
270586000
CY2014Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
4800000
CY2014Q2 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
213550000
CY2014Q2 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
3180000
CY2014Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
121641000
CY2014Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
99607000
CY2014Q2 us-gaap Available For Sale Equity Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleEquitySecuritiesAccumulatedGrossUnrealizedLossBeforeTax
21000
CY2014Q2 us-gaap Assets
Assets
823814000
CY2014Q2 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
6445000
CY2014Q2 us-gaap Inventory Net
InventoryNet
23919000
CY2014Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
84124000
CY2014Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
3770000
CY2014Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
81297000
CY2014Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
270224000
CY2014Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
205312000
CY2014Q2 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
18922000
CY2014Q2 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
80685000
CY2014Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5000000
CY2014Q2 us-gaap Prepaid Taxes
PrepaidTaxes
13609000
CY2014Q2 us-gaap Assets Current
AssetsCurrent
322423000
CY2014Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
6921000
CY2014Q2 mygn Indefinite Lived Intangible Assets Accumulated Amortization
IndefiniteLivedIntangibleAssetsAccumulatedAmortization
CY2014Q2 mygn Indefinite Lived Intangible Assets Gross Excluding Goodwill
IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill
4800000
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
84987000
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
72985000 shares
CY2014Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
72985000 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
38.12
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
22.39
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
23.39
CY2014Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2014Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1082533 shares
CY2014Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2014Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13449874 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
8600742 shares
CY2014Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
65164000
CY2014Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q3 us-gaap Liabilities Current
LiabilitiesCurrent
67725000
CY2014Q3 us-gaap Common Stock Value
CommonStockValue
729000
CY2014Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2368000
CY2014Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
25728000
CY2014Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-17449000
CY2014Q3 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
4617000
CY2014Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
40654000
CY2014Q3 us-gaap Stockholders Equity
StockholdersEquity
712150000
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
809006000
CY2014Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
9588000
CY2014Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
731238000
CY2013Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.34 pure
CY2014Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1343000
CY2014Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
24514000
CY2014Q3 us-gaap Liabilities
Liabilities
96856000
CY2014Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
8382000
CY2014Q3 us-gaap Available For Sale Equity Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleEquitySecuritiesAccumulatedGrossUnrealizedGainBeforeTax
254000
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
69803000
CY2014Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
36000000
CY2014Q3 us-gaap Goodwill
Goodwill
169181000
CY2014Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
43424000
CY2014Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
22674000
CY2014Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
150445000
CY2014Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
236127000
CY2014Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
236357000
CY2014Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
4800000
CY2014Q3 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
211550000
CY2014Q3 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
CY2014Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
33600000
CY2014Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
89807000
CY2014Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
108588000
CY2014Q3 us-gaap Available For Sale Equity Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleEquitySecuritiesAccumulatedGrossUnrealizedLossBeforeTax
24000
CY2014Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
89722000
CY2014Q3 us-gaap Cost Method Investments
CostMethodInvestments
5000000
CY2014Q3 us-gaap Assets
Assets
809006000
CY2014Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
54073000
CY2014Q3 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
13229000
CY2014Q3 us-gaap Inventory Net
InventoryNet
24775000
CY2014Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
54073000
CY2014Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
11244000
CY2014Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
75717000
CY2014Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
236127000
CY2014Q3 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
236357000
CY2014Q3 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
CY2014Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
201962000
CY2014Q3 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
18840000
CY2014Q3 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
89748000
CY2014Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5000000
CY2014Q3 us-gaap Prepaid Taxes
PrepaidTaxes
18698000
CY2014Q3 us-gaap Assets Current
AssetsCurrent
335366000
CY2014Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
89807000
CY2014Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
53928000
CY2014Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
9419000
CY2014Q3 mygn Indefinite Lived Intangible Assets Accumulated Amortization
IndefiniteLivedIntangibleAssetsAccumulatedAmortization
CY2014Q3 mygn Indefinite Lived Intangible Assets Gross Excluding Goodwill
IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill
4800000
CY2014Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
72985326 shares
CY2014Q3 mygn Number Of Restricted Stock Units Issuance As Percentage Of Stock Options Granted
NumberOfRestrictedStockUnitsIssuanceAsPercentageOfStockOptionsGranted
0.3333 pure
CY2013Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.68
CY2013Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
2223000 shares
CY2013Q3 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
90482000
CY2013Q3 us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
0.55
CY2013Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
81798000 shares
CY2013Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.70
CY2013Q3 us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
0.57
CY2013Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5351000 shares
CY2013Q3 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
1638000
CY2013Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79575000 shares
CY2013Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
504000
CY2013Q3 us-gaap Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax
BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax
71003000
CY2013Q3 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
5265000
CY2013Q3 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
9480000
CY2013Q3 us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
14000
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
82904000
CY2013Q3 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
666000
CY2013Q3 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-40000
CY2013Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
56254000
CY2013Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
923000
CY2013Q3 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-1558000
CY2013Q3 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
588000
CY2013Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
83827000
CY2013Q3 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
45371000
CY2013Q3 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
102316000
CY2013Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-439000
CY2013Q3 us-gaap Revenues
Revenues
202467000
CY2013Q3 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
60142000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
55465000
CY2013Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1362000
CY2013Q3 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3379000
CY2013Q3 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
192987000
CY2013Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
285000
CY2013Q3 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1106000
CY2013Q3 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
204351000
CY2013Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6935000
CY2013Q3 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1148000
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16803000
CY2013Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
77279000
CY2013Q3 us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
14000
CY2013Q3 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
11494000
CY2013Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
244000
CY2013Q3 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-19086000
CY2013Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
28362000
CY2013Q3 us-gaap Cost Of Revenue
CostOfRevenue
21439000
CY2013Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2372000
CY2013Q3 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-101511000
CY2013Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
15056000
CY2013Q3 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-8561000
CY2013Q3 us-gaap Costs And Expenses
CostsAndExpenses
119563000
CY2013Q3 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
56846000
CY2013Q3 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
504000
CY2013Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
613000
CY2013Q3 us-gaap Other Cost Of Operating Revenue
OtherCostOfOperatingRevenue
4042000
CY2013Q3 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
791000
CY2013Q3 us-gaap Share Based Compensation
ShareBasedCompensation
6935000
CY2013Q3 mygn Amount Of Reduction In Common Stock As Result Of Stock Repurchases
AmountOfReductionInCommonStockAsResultOfStockRepurchases
29940000
CY2013Q3 mygn Amount Charged To Retained Earnings As Result Of Stock Repurchases
AmountChargedToRetainedEarningsAsResultOfStockRepurchases
72376000
CY2014Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.21
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
3200 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1000 shares
CY2014Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
21.39
CY2014Q3 dei Document Type
DocumentType
10-Q
CY2014Q3 dei Entity Registrant Name
EntityRegistrantName
MYRIAD GENETICS INC
CY2014Q3 dei Trading Symbol
TradingSymbol
MYGN
CY2014Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
3323000 shares
CY2014Q3 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2014Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.38 pure
CY2014Q3 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
6981000
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
38.12
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
shares
CY2014Q3 us-gaap Basis Of Accounting
BasisOfAccounting
<div> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">(1)</font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><u>Basis of Presentation</u></font></td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%; MARGIN-TOP: 6px"> <font style="FONT-FAMILY: Times New Roman" size="2">The accompanying condensed consolidated financial statements have been prepared by Myriad Genetics, Inc. (the &#x201C;Company&#x201D;) in accordance with U.S. generally accepted accounting principles (&#x201C;GAAP&#x201D;) for interim financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (&#x201C;SEC&#x201D;). The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP. The condensed consolidated financial statements herein should be read in conjunction with the Company&#x2019;s audited consolidated financial statements and notes thereto for the fiscal year ended June&#xA0;30, 2014, included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended June&#xA0;30, 2014. Operating results for the three months ended September&#xA0;30, 2014 may not necessarily be indicative of results to be expected for any other interim period or for the full year.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%; MARGIN-TOP: 6px"> <font style="FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%; MARGIN-TOP: 6px"> <font style="FONT-FAMILY: Times New Roman" size="2">Certain reclassifications have been made to prior period amounts to conform to the current period presentation. For the three months ended September&#xA0;30, 2013, a reclassification from proceeds from maturities and sales of marketable securities was made to the effect of foreign exchange rates on cash and cash equivalents in the condensed consolidated statement of cash flows to conform to current-year presentation.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 4%; MARGIN-TOP: 6px"> <font style="FONT-FAMILY: Times New Roman" size="2">Subsequent to the filing of the financial statements in the Company&#x2019;s Form 10-Q as of and for the three months ended September&#xA0;30, 2013, the Company identified an immaterial clerical error in the other comprehensive income items included in the condensed consolidated statements of income and comprehensive income. As a result, the items of other comprehensive income were presented as losses rather than gains, and comprehensive income for the three months ended September&#xA0;30, 2013 was understated. No subsequent filings were impacted. The clerical error has been corrected in the current filing by appropriately reporting the items as gains. The clerical error was not considered material to the condensed consolidated statement of income and comprehensive income and had no effect on any other items on the condensed consolidated statements of income and comprehensive income, including net income and earnings per share. The error also had no effect on the condensed consolidated balance sheet or condensed consolidated statement of cash flows as of and for the three months ended September&#xA0;30, 2013.</font></p> </div>
CY2014Q3 us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
0.21
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
1085733 shares
CY2014Q3 dei Document Period End Date
DocumentPeriodEndDate
2014-09-30
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
24.41
CY2014Q3 dei Amendment Flag
AmendmentFlag
false
CY2014Q3 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2014Q3 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2014Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
76086000 shares
CY2014Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.22
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
83785 shares
CY2014Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
37.17
CY2014Q3 dei Entity Central Index Key
EntityCentralIndexKey
0000899923
CY2014Q3 us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
0.22
CY2014Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35 pure
CY2014Q3 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2014Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
184000 shares
CY2014Q3 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3 Segment
CY2014Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
705944 shares
CY2014Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
25877000
CY2014Q3 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
15982000
CY2014Q3 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
45629000
CY2014Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-98000
CY2014Q3 us-gaap Revenues
Revenues
168837000
CY2014Q3 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
5869000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
15982000
CY2014Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
55000
CY2014Q3 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
276000
CY2014Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
72763000 shares
CY2014Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-721000
CY2014Q3 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
22674000
CY2014Q3 us-gaap Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax
BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax
25920000
CY2014Q3 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
11502000
CY2014Q3 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
4330000
CY2014Q3 us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
1676000
CY2014Q3 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
856000
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
25920000
CY2014Q3 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-69000
CY2014Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
15129000
CY2014Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-43000
CY2014Q3 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
7474000
CY2014Q3 us-gaap Increase Decrease In Prepaid Taxes
IncreaseDecreaseInPrepaidTaxes
5089000
CY2014Q3 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-2689000
CY2014Q3 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1521000
CY2014Q3 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
164507000
CY2014Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-132000
CY2014Q3 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
2498000
CY2014Q3 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
168837000
CY2014Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6880000
CY2014Q3 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
253000
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22612000
CY2014Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
85440000
CY2014Q3 us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
1676000
CY2014Q3 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
7101000
CY2014Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3350000
CY2014Q3 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
4982000
CY2014Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9895000
CY2014Q3 us-gaap Cost Of Revenue
CostOfRevenue
32797000
CY2014Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
5954000
CY2014Q3 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-28854000
CY2014Q3 us-gaap Impairment Of Investments
ImpairmentOfInvestments
0
CY2014Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-15759000
CY2014Q3 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
27576000
CY2014Q3 us-gaap Costs And Expenses
CostsAndExpenses
142917000
CY2014Q3 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
67621000
CY2014Q3 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-721000
CY2014Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2650000
CY2014Q3 us-gaap Other Cost Of Operating Revenue
OtherCostOfOperatingRevenue
2068000
CY2014Q3 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
15099000
CY2014Q3 us-gaap Share Based Compensation
ShareBasedCompensation
6880000
CY2014Q3 mygn Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Canceled In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledInPeriodWeightedAverageGrantDateFairValue
38.12
CY2014Q3 mygn Amount Of Reduction In Common Stock As Result Of Stock Repurchases
AmountOfReductionInCommonStockAsResultOfStockRepurchases
10196000
CY2014Q3 mygn Amount Charged To Retained Earnings As Result Of Stock Repurchases
AmountChargedToRetainedEarningsAsResultOfStockRepurchases
35433000

Files In Submission

Name View Source Status
0001193125-14-397661-index-headers.html Edgar Link pending
0001193125-14-397661-index.html Edgar Link pending
0001193125-14-397661.txt Edgar Link pending
0001193125-14-397661-xbrl.zip Edgar Link pending
d802835d10q.htm Edgar Link pending
d802835dex101.htm Edgar Link pending
d802835dex102.htm Edgar Link pending
d802835dex103.htm Edgar Link pending
d802835dex311.htm Edgar Link pending
d802835dex312.htm Edgar Link pending
d802835dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
mygn-20140930.xml Edgar Link completed
mygn-20140930.xsd Edgar Link pending
mygn-20140930_cal.xml Edgar Link unprocessable
mygn-20140930_def.xml Edgar Link unprocessable
mygn-20140930_lab.xml Edgar Link unprocessable
mygn-20140930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending